Harbor Investment Advisory, LLC Blueprint Medicines Corp Transaction History

Harbor Investment Advisory, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 14, 2023	BUY	$42.2 - $66.37 $5,021 - $7,898	119 Added 10.69%	1,232 $77,000
Q4 2022 Jan 24, 2023	SELL	$41.06 - $66.48 $97,435 - $157,757	-2,373 Reduced 68.07%	1,113 $0
Q2 2021 Jul 27, 2021	BUY	$82.78 - $101.0 $15,397 - $18,786	186 Added 5.64%	3,486 $307,000
Q1 2021 Apr 16, 2021	BUY	$90.71 - $108.28 $9,433 - $11,261	104 Added 3.25%	3,300 $321,000
Q4 2020 Feb 04, 2021	SELL	$92.08 - $124.48 $174,859 - $236,387	-1,899 Reduced 37.27%	3,196 $358,000
Q3 2020 Oct 23, 2020	BUY	$66.45 - $92.7 $71,766 - $100,116	1,080 Added 26.9%	5,095 $472,000
Q2 2020 Jul 16, 2020	BUY	$57.09 - $79.27 $229,216 - $318,269	4,015 New	4,015 $313,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Harbor Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Harbor Investment Advisory, LLC with notifications on news.